Response to the Letter to the Editor Entitled “Critical Reappraisal of Obinutuzumab Randomized Trials in Membranous Nephropathy” Authors: Kajaree Giri, Richard J Glassock, Fernando C Fervenza Published: 2026 The Author Replies: We thank Professor Remuzzi et al.1 for their letter regarding our commentary “Is Obinutuzumab the Answer to Primary Membranous Nephropathy (MN) Resistant to Rituximab?”2 We agree that for the MAJESTY trial, which compared obinutuzumab with tacrolimus in patients with primary membranous nephropathy (NCT04629248) a better comparison would have been against rituximab, the current standard of care. However, considering rituximab’s excellent response rates, to have a head-to-head study showing superiority of obinutuzumab versus rituximab, an end point required for US Food and Drug Administration approval, and assuming a complete remission rate of 35% in rituximab and 45% in obinutuzumab, would have required 1005 randomized patients (at 90% power for an absolute rate difference). Assuming a complete remission rate of 30% in rituximab and 35% in obinutuzumab, it would have required 3684 randomized patients. These would not be feasible scenarios. However, the US Food and Drug Administration would consider approval if obinutuzumab showed superiority over tacrolimus in inducing complete remission. This will be of great benefit for patients, because despite guidelines recommendations, rituximab is not approved by the US Food and Drug Administration for membranous nephropathy in the USA, and it has become increasingly difficult to obtain rituximab’s insurance coverage. The quote by Voltaire “Perfect is the enemy of good,” signifying that overpursuing perfection often hinders the implementation of good and functional improvements applies here. Rigid standards cause inaction, whereas valuable, albeit not perfect, progress is better than no progress at all. A B-cell driven approach3 with rituximab can certainly reduce costs but it is not effective in all patients,4 and higher doses of rituximab appear to affect early remission rates, particularly if phospholipase A2 receptor epitope spreading is present, with higher residual serum rituximab levels at month-3 associated with higher remission rates.5 Furthermore, not all patients respond to rituximab, including those with high anti-phospholipase A2 receptor levels; therefore, there is a need for more effective therapies.6 We entirely agree that a critical perspective and careful interpretation of the data is essential to ensure that the best therapeutic options are adopted. In fact, the authors remind us of the Nobel laureate Sydney Brenner’s quote “it is not proteomics or genomics; it is economics,” arguing that the true challenge in science is not just massive generation of data, but rather the careful management of limited resources. Disclosure FCF has received unrestricted research grants from Genentech Inc and Roche, and was an investigator in the MAJESTY trial. All the other authors declared no competing interests. References